BioWorld

April 21, 2005

View Archived Issues

DOR's OrBec For Treating iGVHD Now On NDA Track

Despite missing the primary endpoint in a pivotal trial for orBec to treat intestinal graft-vs.-host disease (iGVHD), DOR BioPharma Inc. intends to file a new drug application before the end of the year. (BioWorld Today) Read More

Coley's IPO Seeking $115M To Expand Work With TLRs

Read More

Arguments Heard In Supreme Court On Early Research IP

Read More

Molecular Insight Raises $28M In Series C For Imaging Product

Read More

Corgentech Cuts Staff To Slow Spending After E2F Decoy Miss

Read More

With RA Product In Phase II, Merrimack Brings In $28.3M

Read More

Other News To Note

Read More